B Group Inc. Buys 16,785 Shares of Oruka Therapeutics, Inc. $ORKA

B Group Inc. grew its stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 28.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 75,000 shares of the company’s stock after acquiring an additional 16,785 shares during the quarter. Oruka Therapeutics comprises about 0.6% of B Group Inc.’s investment portfolio, making the stock its 15th biggest holding. B Group Inc.’s holdings in Oruka Therapeutics were worth $841,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Legal & General Group Plc purchased a new position in shares of Oruka Therapeutics during the second quarter valued at approximately $28,000. Ameritas Investment Partners Inc. bought a new stake in Oruka Therapeutics in the 2nd quarter worth approximately $31,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Oruka Therapeutics during the 2nd quarter valued at $68,000. New York State Common Retirement Fund bought a new position in shares of Oruka Therapeutics during the 2nd quarter valued at $96,000. Finally, Intech Investment Management LLC purchased a new position in shares of Oruka Therapeutics in the 2nd quarter worth $168,000. 56.44% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on ORKA. BTIG Research upped their price objective on Oruka Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Barclays began coverage on shares of Oruka Therapeutics in a report on Monday, October 13th. They issued an “overweight” rating and a $48.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and set a $40.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 12th. Finally, HC Wainwright dropped their price target on shares of Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Oruka Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.14.

Oruka Therapeutics Stock Performance

ORKA opened at $31.44 on Tuesday. Oruka Therapeutics, Inc. has a fifty-two week low of $5.49 and a fifty-two week high of $31.80. The firm’s fifty day moving average is $26.87 and its 200 day moving average is $18.45. The stock has a market cap of $1.52 billion, a price-to-earnings ratio of -16.55 and a beta of -0.41.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Wednesday, November 12th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. On average, equities research analysts predict that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.